B.
Fireside Chat:
Time:
Virtual viewers: Livestream
About
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-expressing cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Versamune® is a registered trademark and Infectimune™ is a trademark of
Investor Contacts:
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com
Phone: +1 (404) 736-3838
pdsb@cg.capital
Media Contacts:
Dave Schemelia
Phone: +1 (609) 468-9325
dschemelia@tiberend.com
Bill Borden
Phone: +1 (732) 910-1620
bborden@tiberend.com
![](https://ml.globenewswire.com/media/NDRlYjI2NGMtNWExNS00MzU1LTkxMWQtMzVlZTY4ZTU1YTg1LTEwMjg3NjE=/tiny/PDS-Biotechnology-Corporation.png)
2023 GlobeNewswire, Inc., source